Reata Pharmaceuticals 10K Form
7 Day Trial
ALL ACCESS PASS
|2020-08-10||10Q||RETA/Reata Pharmaceuticals Quarterly|
|2020-05-11||10Q||RETA/Reata Pharmaceuticals Quarterly|
|2020-02-19||10K||RETA/Reata Pharmaceuticals Annual|
|2019-11-12||10Q||RETA/Reata Pharmaceuticals Quarterly|
|2019-08-08||10Q||RETA/Reata Pharmaceuticals Quarterly|
|2019-05-09||10Q||RETA/Reata Pharmaceuticals Quarterly|
Receive RETA News And Ratings
See the #1 stock for the next 7 days that we like better than RETA
RETA Financial Statistics
Sales & Book Value
|Price / Cash Flow:||0|
|Price / Book:||0|
|Net Income (TTM):||$-354.18M|
|Return on Equity:||-38758.59%|
|Return on Assets:||-61.85%|
Reata Pharmaceuticals Earnings Forecast
Key Reata Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 7 years for RETA is 100.00%.
- The Selling, General & Administrative Expenses for RETA have been equal to 4,922.52% of Gross Profit Margin.
- The Research & Development expenses have been 7,650.45% of Revenue.
- The Interest Expense is -13.39% of Operating Income.
- The Net Earning history of RETA is -14,049.55% of Total Revenues.
- Per Share Earnings over the last 10 years have been positive in 2 years.
Reata Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
|Trailing P/E Ratio:||0|
|Forward P/E Ratio:||0|
RETA Technical Analysis vs Fundamental Analysis
Reata Pharmaceuticals (RETA) is a Buy
Is Reata Pharmaceuticals a Buy or a Sell?
Reata Pharmaceuticals stock is rated a Buy
The current Reata Pharmaceuticals [RETA] share price is $94.10. The Score for RETA is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.